Abeona Therapeutics (ABEO) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Abeona Therapeutics
Is Abeona Therapeutics a buy right now? The alternative data says hold. This ABEO stock analysis is built on the 25+ alternative data signals AltIndex tracks on Abeona Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $4.52 with a $282M market cap.
The soft spots over the past 90 days: web traffic down 35.4% to 6K monthly visits. The rest of the signal set is holding steady, which keeps ABEO at a hold rather than a sell.
ABEO’s broader alt-data profile also covers job postings (4 open roles), headcount (244 employees, according to LinkedIn), quarterly revenue ($10M), and Facebook followers (3K). Every signal links to its own page with full history, the ABEO technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ABEO is just below.
Abeona Therapeutics AI Stock Analysis
Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious and life-threatening rare genetic diseases. Headquartered in New York, the company aims to leverage its proprietary gene editing and vector delivery platform technologies to target unmet medical needs, particularly those affecting children.
Analysis generated September 29, 2026.
Recent Abeona Therapeutics Stock Alerts
|
Abeona Therapeutics | October 13 Price is down by -6.1% in the last 24h. |
|
Abeona Therapeutics | October 1 Insider Alert: Vasanthavada Madhav is selling shares |
|
Abeona Therapeutics | September 10 Price is down by -6.1% in the last 24h. |
|
Abeona Therapeutics | August 14 Price is down by -6.7% in the last 24h. |
Abeona Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 6K | 35.4% | |
| Job Posts | 4 | N/A | |
| LinkedIn Employees | 244 | 2.5% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 23 | 53.1% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 11K | N/A | |
| X Followers | 2K | N/A | |
| Facebook Followers | 3K | N/A | |
| Facebook Engagement | 0 | N/A |
About Abeona Therapeutics (ABEO)
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
| Price | $4.52 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $282M |
| Year Range | $4 – $7 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Abeona Therapeutics News
View more → |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOAugust 27 - PRNewswire |
 |
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement MilestoneAugust 21 - Yahoo Entertainment |
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 3 - GlobeNewswire |
|
 |
New $25 Million Accelerator Bets On Better Model For Rare DiseaseAugust 13 - Forbes |
Global Regenerative Medicine Market is Projected to Cross the USD 160 Billion Mark by 2034 | DelveInsightAugust 6 - GlobeNewswire |
See Abeona Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ABEO, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEAbeona Therapeutics Earnings & Financial Performance
View all earnings →Abeona Therapeutics Insider Trading Activity
View all →| Vasanthavada Madhav filed to sell 285,721 shares at $0.0. Sep 29 '26 |
| O'Malley Brendan M. filed to sell 421,226 shares at $0.0. Sep 29 '26 |
| Vazzano Joseph Walter filed to sell 482,888 shares at $0.0. Sep 29 '26 |
| Seshadri Vishwas filed to sell 1,286,500 shares at $0.0. Sep 29 '26 |
| Alvino Mark filed to sell 62,065 shares at $0.0. Sep 1 '26 |
Abeona Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Abeona Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Eyepoint PharmaceuticalsEYPT |
$3.07 7.5% | $285M | 32 |
 |
X4 PharmaceuticalsXFOR |
$2.60 7.8% | $280M | 46 |
 |
Vanda PharmaceuticalsVNDA |
$4.30 5.3% | $276M | 47 |
 |
Palisade BioPALI |
$1.47 7.9% | $268M | 48 |
 |
2Seventy BioTSVT |
$4.99 0.0% | $266M | 44 |
Explore Abeona Therapeutics Data
Frequently Asked Questions: Abeona Therapeutics (ABEO)
Abeona Therapeutics has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Abeona Therapeutics (ABEO) stock is $4.52 with a market cap of $282M.
As of today, Abeona Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Abeona Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Abeona Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ABEO stock price chart above shows Abeona Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Abeona Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Abeona Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
